StockData
Emergent BioSolutions Inc. logo

Emergent BioSolutions Inc. (EBS) company profile

EBSNYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/3074% below fair value
$5.61−0.20 (-3.44%)

Close on Nov 17, 2026Market cap $287.64MP/E –Yield –

About Emergent BioSolutions

Pharmaceutical Preparations, SIC 2834

The company is a life sciences enterprise that develops and supplies medical solutions to address public health threats, including chemical, biological, and nuclear hazards, infectious diseases, and emergency health crises. Its operations comprise three primary segments: Commercial Products, Medical Countermeasures, and Services. The Commercial segment supplies opioid overdose treatments, notably NARCAN and KLOXXADO nasal sprays. The Medical Countermeasures segment provides vaccines and therapeutics against severe threats such as smallpox, anthrax, and botulism, featuring ACAM2000, BioThrax, and BAT. The Services segment delivers contract development and manufacturing capabilities for external clients. Its customers include the United States government, foreign governments, healthcare departments, law enforcement agencies, community organizations, pharmacies, and commercial biopharmaceutical companies.

The company operates four development and manufacturing facilities across the United States and Canada, located in Gaithersburg, Canton, Lansing, and Winnipeg. It delivers products globally, supplying medical countermeasures to international partners and distributing its botulism antitoxin to nineteen foreign countries. The provided text does not state the location of its headquarters.

Summary of the business section of Emergent BioSolutions's latest annual report, written by StockData.

Company profile

Company

Legal name
Emergent BioSolutions Inc.
Founded
1998
Headquarters
Gaithersburg, MD
Address
300 Professional Dr 20879
Phone
(240) 631-3200
Employees
900, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, Tysons, Virginia

Stock & identifiers

Ticker
EBS
Exchange
NYSE
IPO date
Nov 15, 2006
Shares outstanding
51M, Jul 30, 2026
Public float
$342.70M, Jun 30, 2025
Filer category
Accelerated filer
SEC CIK
1367644
CUSIP
29089Q105
ISIN
US29089Q1058
FIGI
BBG000GW06J7
Share class FIGI
BBG001SP1G40
LEI
549300YW6TUOX8BE5103
EIN
14-1902018

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Zsolt HarsanyiChairman, Director149,076
Joseph C. PapaPresident and CEO, Director493,153
Paul Anthony WilliamsSVP, Products Business156,098
Stephanie DuatschekEVP, CGO197,416
Richard S. LindahlEVP, Chief Financial Officer374,083
Coleen GlessnerEVP, Quality & Ethics, and CPL202,201
William HartzelSVP, Bioservices185,558
Jessica PerlSVP, General Counsel, Corp Sec165,286
Simon C. LowrySVP, R&D, CMO177,914
Donald W. DeGolyerDirector111,921
John D. Fowler JrDirector30,350
Marvin L. WhiteDirector113,839
Ronald RichardDirector123,761
Keith KatkinDirector96,294
Kathryn C. ZoonDirector80,998
Neal Franklin FowlerDirector160,847
Sujata Tyagi DayalDirector101,543
Louis W. SullivanDirector139,098

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$5.32M$9.36M$1.81M$14$171
FY2024
Miller
$218.75K$218.75K$1.79M$18$147
FY2024
Papa
$5.86M$19.53M$1.79M$18$147
FY2023
Kramer
$5.10M$393.08K$1.81M$4$146
FY2023
Miller
$766.67K$766.67K$1.81M$4$146
FY2023
Mr.Kramer
$5.10M$393.08K$1.81M$4$146

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Joseph Papa
President, Chief Executive Officer and Director
$1.04M$1.64M$1.19M$1.45M$7.12K$5.32M-9%
Richard Lindahl
Executive Vice President, Chief Financial Officer
$662.02K$851.95K$753.05K$431.20K$10.50K$2.71M+17%
Coleen Glessner
Executive Vice President, Quality and Ethics and Compliance
$623.55K$362.50K$263.61K$406.08K$8.52K$1.66M-19%
Simon Lowry
Chief Medical Officer and Head of Research and Development
$545.00K$362.50K$263.61K$289.67K$10.50K$1.47M–
Paul Williams
Senior Vice President, Products Business
$495.02K$362.50K$263.61K$262.61K$7.43K$1.39M-17%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Nov 15, 2006
Offer price
$12.50
Securities offered
5,000,000
Gross proceeds
$62.50M
Exchange
NYSE
First trading day
Nov 15, 2006
First-day close
$11.70-6.4%
Lock-up ends (est.)
May 14, 2007

“Our common stock has been authorized for listing on the New York Stock Exchange under the symbol “EBS.” Per share Total Initial public offering price $ 12.500 $ 62,500,000 Underwriting discounts and commissions $ 0.875 $ 4,375,000 Proceeds to Emergent, before expenses $ 11.625 $ 58,125,000 The underwriters have an option for a period of 30 days to purchase up to 480,000 additional shares of common stock from the sell”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had approximately 900 employees globally.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?